Table 3 Adjusted hazard ratios of 5-year surgical complications after midurethral sling surgery, stratified by subgroups of age and diabetes mellitus.

Age ≤ 65 years

Diabetes mellitus

No

1429

50

Ref

Yes

94

5

1.793 (0.669, 4.807)

Surgical duration (h)

1523

55

1.111 (0.912, 1.355)

Menopausal syndrome diagnosis

No

1389

45

Ref

Yes

134

10

2.222 (0.982, 5.029)

Hormone replacement therapy

No

1360

42

Ref

Yes

163

13

1.384 (0.596, 3.215)

Average flow rate (ml/s)

1423

55

0.929 (0.853, 1.012)

TVT-O sling type

TOT

475

12

Ref

TVT-O

885

32

1.235 (0.598, 2.547)

Age > 65 years

Diabetes mellitus

No

354

30

Ref

Yes

84

8

1.185 (0.476, 2.952)

Surgical duration (h)

438

38

0.966 (0.697, 1.338)

Menopausal syndrome diagnosis

No

378

33

Ref

Yes

60

5

0.618 (0.146, 2.618)

Hormone replacement therapy

No

316

21

Ref

Yes

122

17

2.131 (0.880, 5.163)

Average flow rate (ml/s)

423

35

1.036 (0.893, 1.201)

TVT-O sling type

TOT

145

7

Ref

TVT-O

253

23

1.392 (0.516, 3.754)

Diabetes mellitus

Age (year)

178

13

1.013 (0.959, 1.069)

Surgical duration (h)

178

13

1.630 (0.971, 2.735)

Menopausal syndrome diagnosis

No

162

12

Ref

Yes

16

1

0.000 (0.000, 0.000)

Hormone replacement therapy

No

143

10

Ref

Yes

35

3

0.340 (0.036, 3.207)

Average flow rate (ml/s)

170

12

1.049 (0.923, 1.193)

TVT-O sling type

TOT

83

4

Ref

TVT-O

87

8

1.249 (0.400, 3.895)

Non-diabetes mellitus

Age (year)

1783

80

1.015 (0.989, 1.041)

Surgical duration (h)

1783

80

1.023 (0.847, 1.235)

Menopausal syndrome diagnosis

No

1605

66

Ref

Yes

178

14

1.504 (0.743, 3.046)

Hormone replacement therapy

No

1533

53

Ref

Yes

250

27

2.239 (1.235, 4.057)*^,a

Average flow rate (ml/s)

1676

78

0.940 (0.860, 1.028)

TVT-O sling type

TOT

537

15

Ref

TVT-O

1051

47

1.191 (0.611, 2.321)